Article Text

other Versions

PDF
Latest insights in therapeutic options for systemic right ventricular failure: a comparison with left ventricular failure.
  1. Michiel M Winter (m.m.winter{at}amc.uva.nl)
  1. Academic Medical Center, Netherlands
    1. Berto J Bouma (b.j.bouma{at}amc.uva.nl)
    1. Academic Medical Center, Netherlands
      1. Maarten Groenink (m.groenink{at}amc.uva.nl)
      1. Academic Medical Center, Netherlands
        1. Thelma C Konings (t.konings{at}vumc.nl)
        1. VU Medical Center, Netherlands
          1. Jan GP Tijssen (j.tijssen{at}amc.uva.nl)
          1. Academic Medical Center, Netherlands
            1. Dirk J van Veldhuisen (d.j.van.veldhuisen{at}thorax.umcg.nl)
            1. University Medical Center Groningen, Netherlands
              1. Barbara JM Mulder (b.j.mulder{at}amc.uva.nl)
              1. Academic Medical Center, Netherlands

                Abstract

                The number of adult patients with a systemic right ventricle (RV) is steadily increasing. Survival is relatively good in these patients, but deterioration of the systemic RV seems inevitable. Although therapeutic options for patients with LV failure are well established, their role in patients with systemic RV failure is often undefined. To appreciate the potency of LV failure therapy in patients with a systemic RV, insight into pathophysiology of systemic RV failure and into recent developments in therapeutic research are indispensible. This review provides these insights, and will facilitate and ameliorate therapeutic decision making in patients with a systemic RV.

                Statistics from Altmetric.com

                Request permissions

                If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.